XML 38 R21.htm IDEA: XBRL DOCUMENT
v3.24.1

Research and Development Costs (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Research and Development [Abstract] |
Schedule of Research and Development Costs | A summary of research and development costs for the years ended December 31, 2023 and 2022, including costs associated with clinical trials involving the Company’s lead clinical compound LB-100, are summarized below based on the respective geographical regions where such costs have been incurred. Schedule of Research and Development Costs
|  | 2023 |  |  | 2022 |
|  | Years Ended December 31, |
|  | 2023 |  |  | 2022 |
United States |  | $ | 359,589 |  |  | $ | 350,618 |
Spain |  |  | 295,163 |  |  |  | 626,366 |
France |  |  | — |  |  |  | 91,532 |
China |  |  | 17,198 |  |  |  | 76,595 |
Netherlands |  |  | 226,150 |  |  |  | 204,158 |
Total |  | $ | 898,100 |  |  | $ | 1,349,269 |
Research and development costs |  | $ | 898,100 |  |  | $ | 1,349,269 |

X
- Definition Schedule Of Research And Development Costs [Table Text Block] + References No definition available. + Details
Name: | LIXT_ScheduleOfResearchAndDevelopmentCostsTableTextBlock
Namespace Prefix: | LIXT_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration